article · Discover Applied Sciences
Solid lipid nanoparticles provide a flexible colloidal platform designed specifically for formulating hydrophobic drugs. Multiple production methodologies, such as high-pressure homogenisation and microemulsion techniques, directly dictate the physical characteristics and therapeutic performance of these nanocarriers. By encapsulating active compounds within a protective lipid matrix, these systems shield drugs from degradation across various administration routes, which enhances overall treatment efficacy. The nanocarriers also exhibit sustained release profiles that prolong delivery times and lower the frequency of required doses. Due to their minute particle size and extensive surface area, solid lipid nanoparticles improve drug dissolution rates, elevate bioavailability, and lengthen retention periods inside the body. The existing landscape includes multiple patents and globally accessible commercial formulations, demonstrating sustained progress in refining these delivery platforms for diverse therapeutic uses.
Many therapeutic drugs fail to work effectively because they do not dissolve well in water or break down too quickly inside the body. Solid lipid nanoparticles resolve this by acting as tiny protective carriers. They shield vulnerable medicines, release them steadily over time, and ensure that larger amounts of the active treatment are successfully absorbed, leading to better outcomes for patients with fewer required doses.
Solid lipid nanoparticles are already at an advanced commercial stage, as evidenced by multiple patents and formulations available globally. Pharmaceutical developers can utilise techniques like high-pressure homogenisation to create sustained-release treatments for hydrophobic drugs across various administration routes. Ongoing technical refinements focus on overcoming remaining processing hurdles and expanding into novel therapeutic avenues, offering immediate value for drug reformulation and delivery specialists.
AI-generated from the published abstract. Always read the original work before citing.
Abstract Lipid-based colloidal carriers, particularly Solid Lipid Nanoparticles (SLNs), offer a versatile platform for formulating hydrophobic drugs, presenting significant pharmaceutical implications across diverse fields. This paper explores methodologies utilized in SLN production, ranging from high-pressure homogenization to microemulsion techniques, with each method influencing the characteristics and efficacy of the resultant nanoparticles. Various administration routes for SLNs exist, leveraging the lipid matrix's protective properties to shield encapsulated drugs, thus minimizing degradation and enhancing therapeutic efficacy. Furthermore, SLNs exhibit sustained release properties, facilitating prolonged drug delivery and reducing the need for frequent dosing. Their small size and high surface area contribute to improved drug dissolution, enhanced bioavailability, and extended retention within the body. The existence of multiple patents underscores the substantial research conducted in the domain of SLNs, with numerous commercial formulations available globally. In conclusion, this work highlights the intricate nature of SLNs and their pivotal role in advancing drug delivery techniques. Ongoing efforts are directed toward overcoming challenges and exploring novel therapeutic avenues, highlighting the dynamic and evolving landscape of SLN research and application.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1007/s42452-024-05897-z
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
